Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COLUMN
When Interviewing, Share the Love
Philip Carrigan Several years ago, I searched for a brand director for Advair in Japan. GlaxoSmithKline’s marketing director for the product was a tall, charismatic American. He aimed to take the marketing team from providing communication support for the detailmen…
To read the full story
COLUMN
- Why Your Brain Wants You to Stay (Even When You Want to Go)
July 31, 2026
- The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard
June 26, 2026
- More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry
May 29, 2026
- The Patient North Star: How Gilead Japan Redefined Innovation
April 8, 2026
- Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
March 27, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…